Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Investor Presentation (June 2025)
39 slides from Vivani Medical's investor presentation, Jun 17, 2025
Slide 1: Vivani Medical, Inc.
Slide 2: Disclaimers
Disclaimers “The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Secures Act of 1933, as amended, and Section 21F of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the “safe harb
Slide 3: Vivani Executive Leadership Team
Vivani Executive Leadership Team ") Adam Mendelsohn PhD - CEO/Director * Co-founder/Co-inventor of Vivani technology + PhD Bioengineering (UCSF/UC Berkeley) ) + Management of Technology Certificate at Haas School of Business + Research focused on diabetes treatment + Formerly at Boston Scientific an
Slide 4: Vivani Headquarters and GMP Manufacturing Facility
Vivani Headquarters and GMP Manufacturing Facility 1350 S. Loop Road, Alameda, California since 2023
Slide 5: Vivani Medical, Inc.
Vivani Medical, Inc. © OOO ‘An innovative, clinical-stage biopharmaceutical company developing a portfolio of ultra long- acting, miniature, drug implants to treat chronic diseases. NanoPortal™ platform technology enables the design of implants aimed at improving medication non-adherence and tolerab
Slide 6: Company Pipeline
Company Pipeline If Approved, Vivani Products will Compete in Markets with Large Potential Indication Feasibility Pre-Clinical Clinical Market Size* NPM-115, high-dose exenatide NPM-119 exenatide NPM-139 OKV-119** >$0.5B ‘exenatide + Estimated Market Sizes where Vivani products would compete, if app
Slide 7: Drug Implants
Drug Implants Proprietary Platform Technology
Slide 8: GLP-1 Implant and Applicator
GLP-1 Implant and Applicator NanoPortal"® Membrane 000, Vivani
Slide 9: Nanotube Membrane
Nanotube Membrane
Slide 10: NanoPortal: How it Works
NanoPortal™ How it Works... By precisely adjusting the nanotube pore size to slightly greater than the size of specific drug molecules, the interactions between the drug and nanotube walls can result in desirable release profiles over time, including near constant release ° eve Pore too s Pore targe
Slide 11: Minimal Fluctuations with 2.5-hour interval sampling
Minimal Fluctuations with 2.5-hour interval sampling — high Dose, n=6. —— Low Dose, n=6 Individual Release Profiles (n=6) Ze Ze @ & 3 2 4 Tip jis ty dH zo i 2 i 20 3S Sea ws 0 5 7000 Time (Days) ‘Time (Days) and ~4 yg for the low-dose. Values are mean + SD. (11)
Slide 12: NanoPortal is a Platform Technology
NanoPortal™ is a Platform Technology Broad Potential Application Can Support Portfolio of New Drug Implants Tunable Di ry Rate
Slide 13: Six-month exenatide implant
Six-month exenatide implant NanoPortal™ Six-month exenatide implant Osmotic Pump (Intarcia) (Vivani) jorersena) —e) Ta” + FDAalleges that daily variations in drug release + Minimally fluctuating drug release profile may be responsible for clinical safety signals which observed in pre-clinical studie
Slide 14: Exenatide daily release comparison
Exenate dy release meg) Osmotic Pump, ITCA 650 Tie (6) In vtro dat, including dally release intervals, from the 4 TCA 650 devices with the highest day-to-day variabilty out of 12 tested, presented by FDA during September 2023 ‘Advisory Committee Hearing with Intarcia “Tne cine data i the tres pivota
Slide 15: Medication non-adherence and tolerability are significant unmet needs for GLP-1 treatments
‘Medication non-adherence and tolerability are significant unmet needs for GLP-1 treatments & Adherence/Persistence to GLP-1s is suboptimal, at only ~30-40% adherent patients during year one and = '~36-47% persistence by end of year one (Ozempic/Wegovy)'. Discontinuation leads to immediate hunger- r
Slide 16: Vivani Lead Program: NPM-115
Vivani Lead Program NPM-115 High-Dose Exenatide Implant for Chronic Weight Management Targeting the Rapidly Growing GLP-1 RA Market
Slide 17: Tremendous unmet medical need in Obesity
+ Tremendous unmet medical need in Obesity’: + 764M people living with obesity + 15M (2%) taking an anti-obesity medication + GLP-1 monotherapy may provide adequate weight loss for the majority of patients? + Preclinical data with NPM-115 has demonstrated similar magnitude of weight loss for exenati
Slide 18: Large Retrospective Cohort Study (N=1,911)
Large Retrospective Cohort Study* (N=1,911) Weight Loss Medicines Associated With 100% Adherence Challenges vss Recent retrospective cohort study 50% (n=1,911) reported improved medication persistence with semaglutide of 40% after one year 25% Percent Remaining on Therapy 3 improvement in persistenc
Slide 19: Body weight change and rebound hunger after GLP-1 withdrawal
Body weight (%) - change from baseline Time since randomization (wk) STEP 1 Extension: Semaglutide Withdrawal ‘auyjaseg wou afueu - (>) auBiam Apog 1000 g Food Consumption vs Control (4) ry S & 1000 ° SE Sroapt Sham plat Coneah P TS roup 2° NPE tap 3-NPALTE oetment econo at ay 10-2 Te Sr Osan Greate
Slide 20: Exenatide implant reduces liver fat by 82% in obese mice
Exenatide implant reduces liver fat by 82% in obese mice after 12 weeks Liver fat reduction in high fat diet-induced obese mice. Liver fat % area for exenatide implant vs sham implant 12 weeks after a single administration. Liver fat % area is calculated using Oil Red O (ORO) staining. Values are m
Slide 21: Exenatide with NanoPortal associated with durable body weight effects
Exenatide delivered with NanoPortal™ technology is associated with durable body weight effects Weight difference from control in healthy Sprague-Dawley Rats. % weight change from baseline for a single administration of exenatide implant in a study associated with NPM-119 (~320 nmol/kg/day) correcte
Slide 22: Weight difference from control in Sprague-Dawley rats
Imlat reves 50 50 A B Wee tt terete eee ee z = Bor B07 z z i \ “150 § -00} | 8 z % 0b Ps 2 -150 2 so 5 5 a 3 3 a — rs ~ -20 aa “350 I “794 Vehicle Implant (Control), n=18 40.0 |. “4 Vehicle Implant (Control), © Exenatide Implant. n=24 = Exonatide Implant, n=5 on -450 rr ow a 4s 6075 a0 tbs 120 135 T
Slide 23: In vivo and in vitro performance of 12-week exenatide implant
Jn vivo and in vitro performance of 12-week exenatide implant configuration to be studied in LIBERATE-1 A sham implant Conton), »=7 ‘Exenatide Implant, 1=7 plants to occur at day 120 z £ Poo 3 in UBERATE ? 5 3 ca | Ey 2 2 2 ra 8 8 é 20 2 40 E & 5 z= 20 [ee ee ee er Mean, n=17 === Upper + Lowor 95% C
Slide 24: Pharmacokinetics of 6-month exenatide implant in rats
14 : - 8 22 ad cr mas e210 z8 Bo 95 ge 5 3 so 82 ze ge 3 2038 a4 : H 2 1° & ° Ca a Time (Days) Pharmacokinetics of 6-month exenatide implant in male Sprague-Dawley rats (n=6) Exenatide antibody-positive animals are not included inthis data set. Values are mean 2 SD. #2 of 6 implants are responsible
Slide 25: LIBERATE-1 study design
Primary Objectives: _ Safety/tolerability assessment and full pharmacokinetic characterization. Changes in weight will also be assessed. Key Inclusion/Exclusion Criteria: 18-55 years old; overweight or obese (BMI 27-40) Otherwise healthy (no T2DM, normal renal function) Screen unin tandomize reatmen
Slide 26: NPM-115 Clinical + Regulatory Development
NPM-115 Clinical + Regulatory Development 2023 2024 2024 2025 2025 2025 Near-Term Plan Announced NPM-115 Program to Evaluate High Dose Exenatide November 2023 Implant for Chronic Weight Management Reported Positive Weight Loss in Preclinical Study February 2024 ‘Announced Initiation of Screening and
Slide 27: NPM-119 Exenatide Implant for Type 2 Diabetes
NPM-119 Exenatide Implant for Type 2 Diabetes Targeting the Rapidly Growing GLP-1 RA Market
Slide 28: Significant unmet need in Diabetes
+ Significant unmet need in Diabetes": + 537M people living with diabetes * ~ 15% in good control + Non-adherence is the primary reason for low, real-world effectiveness?? + Guaranteed adherence will produce significant healthcare cost savings* + FDA indicated 505(b)(2) streamlined approval pathway
Slide 29: Current Drug Real-World Adherence of Select Drugs
Current Drug Real-World Adherence of Select Drugs Adherence Challenge 100% “Drugs don't work in people that don't take them” 75% NPM-119* Designed to Enable 100% Adherence through Implant Duration 50% + Orals and injectables do not guarantee adherence + Approximately 50% of patients donot meet : ‘gl
Slide 30: Patient research indicates strong adoption potential
Patient research indicates strong adoption potential for a miniature, 6-month exenatide implant PWD sentiment towards the ITCA 650 concept is more strongly positive amongst those who are currently on a GLP-1 RA or who have taken one in the past. Lkelinood of getting ITCA 650 exenatide Implant It FDA
Slide 31: Prescriber and Payer research also provide strong support
Prescriber and Payer research also provide strong support iature, 6-month exenatide implant Prescribing Rati ne. Average 8.3 out a Adherence = Lower Acute Care & Outpatient Costs ang Oval uta scale Ft 10. where src at a Hey and 10 bl eel por pains (rerremay ley now ikely sre yout proeroa NPM 13? bat
Slide 32: Vivani Lead Program: NPM-139
Vivani Lead Program NPM-139 Semaglutide Implant for Chronic Weight Management Targeting the Rapidly Growing GLP-1 RA Market
Slide 33: Semaglutide products and NPM-139 implant
+ Semaglutide products Ozempic® and Wegovy® generated ~$25B in sales in 2024 + More than half of patients regularly miss doses based on real-world adherence data + NPM-139 is initially being designed for once or twice-yearly dosing. + In addition to obesity, the semaglutide implant is also under con
Slide 34: Body weight measurements of semaglutide implant
AWeight (vs Control) OPP PP PPP PHL PHP POOH Time (Days) Body weight measurements of semaglutide implant (n=7). Weight difference versus control group in healthy Sprague-Dawley Rats. ‘weight change from baseline for NPM-139 (semaglutide implant) corrected to control (sham implant). Values are mean +
Slide 35: Financial Information
Vivani Medical, Inc. Financial Information
Slide 36: Condensed Consolidated Statement of Operations
Condensed Consolidated Statement of Operations In Thousands, except Share Data Operating expenses: Research and development, net of grants General and administrative Total operating expenses Loss from operations ‘Other income (expense), net Net income/(loss) Net income/(loss) per common share - basi
Slide 37: Condensed Consolidated Balance Sheet
tw thousands (Mar.31.2025 Dec. 31.2028 (unaudited) (audited) LIABILITIES AND STOCKHOLDERS: EQUITY “Current iabiities $ 0198 $5900 Long term operating tease abies 37.629 17.965 ‘otal babuities 23.828 23.051 ‘Total Comman Stock, AIC &OmerCompGain «130,850 130,534 ‘Accumulated denier (428.226) (121,824
Slide 38: As of March 31, 2025
As of March 31, 2025 Pe De Deas ‘Common Stock Stock Options RSUs Warrants Fully Diluted Shares “Weighted Average Exercise Price 59,243,903 $2.47 7,051,195 695,000 $3.45 8,569,894 75,559, 992
Slide 39: Vivani Medical, Inc.
Vivani Medical, Inc. © OOO ‘An innovative, clinical-stage biopharmaceutical company developing a portfolio of ultra long- acting, miniature, drug implants to treat chronic diseases. NanoPortal™ platform technology enables the design of implants aimed at improving medication non-adherence and tolerab